Emmaus Life Sciences Incorporation (EMMA)

Sector:
HEALTH CARE
Industry:
HEALTH CARE SERVICES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Yutaka Niihara
Employees:
60
21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE, CA, 90503
310-214-0065

Emmaus Life Sciences, Inc. discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Data derived from most recent annual or quarterly report
Market Cap 63.963 Million Shares Outstanding49.584 Million Avg 30-day Volume 30.405 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.06
Price to Revenue0.5442 Debt to Equity-0.7796 EBITDA-4.683 Million
Price to Book Value0.0 Operating Margin-65.45870000000001 Enterprise Value4.015 Million
Current Ratio0.154 EPS Growth-11.743 Quick Ratio0.064
1 Yr BETA 0.6037 52-week High/Low 0.0 / Profit Margin-114.2571
Operating Cash Flow Growth-2729.3269 Altman Z-Score-9.4506 Free Cash Flow to Firm 13.557 Million
View SEC Filings from EMMA instead.

View recent insider trading info

Funds Holding EMMA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EMMA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-01-19:
    Item 3.02: Unregistered Sales of Equity Securities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-12:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-09-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-13:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    2 Million total shares from 1 transactions

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ZEN WEI PEU

    • Director
    2,000,000 2023-01-18 2

    NIIHARA YUTAKA CHAIRMAN AND CEO

    • Officer
    • Director
    • 10% Owner
    0 2023-01-12 18

    LEE WILLIS C COO

    • Officer
    • Director
    500,000 2023-01-12 6

    NAGASAKI YASUSHI CFO

    • Officer
    150,000 2023-01-12 1

    ZWICKER IAN HARVEY

    • Director
    100,000 2023-01-12 2

    SEKULICH GEORGE CIO & SVP

    • Officer
    100,000 2023-01-12 1

    STARK CHARLES WILLIAM SVP, CLINICAL DEVELOPMENT

    • Officer
    100,000 2023-01-12 1

    LIM SEAH H.

    • Director
    100,000 2023-01-12 2

    TERANISHI LORI

    • Director
    18,161 2022-01-06 0

    LUI ALFRED FU KONG

    • Director
    42,358 2022-01-03 0

    WOOD JANE PINE

    • Director
    0 2020-03-25 0

    DICKEY ROBERT IV

    • Director
    0 2019-07-17 0

    TRAN LAN T. CHIEF ADMINISTRATIVE OFFICER

    • Officer
    26,562 2019-07-17 0

    OSATO MASAHARU

    • Director
    518,367 2019-07-17 0

    SHERWOOD JOSEPH CHARLES III CHIEF FINANCIAL OFFICER

    • Officer
    0 2019-07-17 0

    D'AMBROSIO DONALD ERIC CHIEF FINANCIAL OFFICER

    • Officer
    0 2019-06-25 0

    PAPPAJOHN JOHN

    • Director
    • 10% Owner
    1,117,925 2019-05-23 0

    SMITH ROBIN L

    • Director
    211,539 2019-05-08 0

    HERGUTH PATRICK CHIEF EXECUTIVE OFFICER

    • Officer
    0 2018-12-12 0

    CARPENTER GEORGE C IV CHIEF INNOVATION OFFICER

    • Officer
    0 2018-12-12 0

    HARRIS GEOFFREY E.

    • Director
    97,110 2018-10-08 0

    VOTRUBA MICHAL

    • Director
    0 2018-10-08 0

    RSJ INVESTMENTS SICAV A.S. ACTING IN RESPECT OF ITS SUB-FUND (PODFOND) RSJ GRADUS PODFOND, RSJ INVESTMENT SICAV A.S.

    • 10% Owner
    1,056,474 2018-10-08 0

    UNANUE PETER

    • Director
    126,627 2018-10-08 0

    TIERNEY THOMAS T

    • Director
    • 10% Owner
    236,345 2016-11-30 0

    MCADOO ZACHARY

    • FORMER DIRECTOR
    No longer subject to file 2016-11-01 0

    BUCK PAUL CHIEF FINANCIAL OFFICER

    • Officer
    0 2016-11-01 0

    SASSINE ANDY

    • FORMER DIRECTOR
    No longer subject to file 2016-11-01 0

    FOLLMAN ROBERT J

    • Director
    167,781 2016-11-01 0

    OMAN MARK C

    • 10% Owner
    0 2015-12-23 0

    SCHINDLER WALTER

    • Director
    6,069,376 2014-07-11 0

    TURNER RICHARD W

    • Director
    0 2013-05-23 0

    DARKOCH MICHAEL EXECUTIVE VP & CMO

    • Officer
    53,333 2012-11-28 0

    JONES DAVID B

    • Director
    • 10% Owner
    0 2011-02-28 0

    JONES DAVID B

    SAIL VENTURE PARTNERS LP

    SAIL VENTURE PARTNERS LLC

    • Director
    • 10% Owner
    1,707,500 2010-11-03 0

    KALLINS GEORGE J

    • Director
    1,441,166 2010-11-03 0

    HARBIN HENRY T

    • Director
    0 2010-03-03 0

    THOMPSON TOMMY G

    • Director
    0 2010-03-03 0

    VACCARO JEROME

    • Director
    0 2010-03-03 0

    HOFFMAN DANIEL A PRESIDENT AND CMO

    • Officer
    0 2010-03-03 0

    BRANDT LEONARD J.

    • Director
    • 10% Owner
    8,890,795 2009-08-26 0

    SAIL VENTURE PARTNERS LP

    • 10% Owner
    3,632,711 2009-06-30 0

    SAIL VENTURE PARTNERS LLC

    • 10% Owner
    3,632,711 2009-06-30 0

    LUCE BRADLEY V.P. FINANCE & CONTROLLER

    • Officer
    No longer subject to file 2008-09-17 0

    HERTZ HORACE CFO

    • Officer
    651,250 2007-08-08 0

    PHILLIPS SILAS A CEO, CFO AND SECRETARY

    • Officer
    • Director
    322,674 2006-07-18 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    ZEN WEI PEU - Director

    2023-01-20 11:40:58 -0500 2023-01-18 P 2,000,000 $0.50 a 2,000,000 direct

    NIIHARA YUTAKA - Director - Officer - > 10% Owner CHAIRMAN AND CEO

    2023-01-17 13:59:20 -0500 2023-01-12 A 7,500,000 $4.50 a 0 direct

    LEE WILLIS C - Director - Officer COO

    2023-01-17 14:27:49 -0500 2023-01-12 A 750,000 $4.50 a 750,000 direct

    NAGASAKI YASUSHI - Officer CFO

    2023-01-17 14:29:30 -0500 2023-01-12 A 150,000 $4.50 a 150,000 direct

    SEKULICH GEORGE - Officer CIO & SVP

    2023-01-17 14:31:02 -0500 2023-01-12 A 100,000 $4.50 a 100,000 direct

    STARK CHARLES WILLIAM - Officer SVP, CLINICAL DEVELOPMENT

    2023-01-17 14:32:23 -0500 2023-01-12 A 100,000 $4.50 a 100,000 direct

    LIM SEAH H. - Director

    2023-01-17 14:34:14 -0500 2023-01-12 A 100,000 $4.50 a 100,000 direct

    ZEN WEI PEU - Director

    2023-01-17 14:35:49 -0500 2023-01-12 A 100,000 $4.50 a 100,000 direct

    ZWICKER IAN HARVEY - Director

    2023-01-17 14:36:53 -0500 2023-01-12 A 100,000 $4.50 a 100,000 direct

    LEE WILLIS C - Director - Officer COO

    2023-01-19 17:54:15 -0500 2023-01-12 A 500,000 $4.50 a 500,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 22:15:03 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 21:45:03 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 21:15:03 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 20:45:06 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 20:15:04 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 19:45:03 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 19:15:04 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 18:45:03 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 18:15:03 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 17:45:03 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 17:15:04 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 16:45:04 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 16:15:03 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 15:45:03 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 15:15:03 UTC -10.6248 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 14:45:04 UTC -10.8748 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 14:15:04 UTC -10.8748 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 13:45:03 UTC -10.8748 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 13:15:03 UTC -10.8748 15.1948 400000
    EMMAUS LIFE SCIENCES INC EMMA 2023-02-03 12:45:03 UTC -10.8748 15.1948 400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments